ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

2:00PM-3:30PM: Abstract Number: 1638

CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden

Abstracts: Sjögren’s Syndrome – Basic & Clinical Science

2:00PM-3:30PM: Abstract Number: 1626

Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study

Abstracts: Pediatric Rheumatology – Clinical II: Connective Tissue Disease

2:00PM-3:30PM: Abstract Number: 1593

Combining Single-cell RNA Sequencing and Population-based Studies Reveals Hand Osteoarthritis-associated Chondrocyte Subpopulations and Pathways

Abstracts: Osteoarthritis & Joint Biology – Basic Science

2:00PM-3:30PM: Abstract Number: 1617

Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022

Abstracts: Health Services Research II

2:00PM-3:30PM: Abstract Number: 1631

Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, & Outcomes II: Comorbidities

2:00PM-3:30PM: Abstract Number: 1605

Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)

Abstracts: Antiphospholipid Syndrome

2:00PM-3:30PM: Abstract Number: 1591

Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis

Abstracts: Osteoarthritis & Joint Biology – Basic Science

2:00PM-3:30PM: Abstract Number: 1636

Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study

Abstracts: Sjögren’s Syndrome – Basic & Clinical Science

2:00PM-3:30PM: Abstract Number: 1635

Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies

Abstracts: Sjögren’s Syndrome – Basic & Clinical Science

2:00PM-3:30PM: Abstract Number: 1585

Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure

Abstracts: Innate Immunity

2:00PM-3:30PM: Abstract Number: 1612

Design and Validation of a Comparator for Randomized Controlled Trials of a Digital Cognitive Behavioral Therapy

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

2:00PM-3:30PM: Abstract Number: 1623

Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort

Abstracts: Pediatric Rheumatology – Clinical II: Connective Tissue Disease

2:00PM-3:30PM: Abstract Number: 1610

Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes

2:00PM-3:30PM: Abstract Number: 1633

Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease

Abstracts: Sjögren’s Syndrome – Basic & Clinical Science

2:00PM-3:30PM: Abstract Number: 1589

Epigenetic Regulation of DNMT3A by TFEB and DOT1L Through AMPK Signalling Orchestrates the Lysosomal Response of Macrophages During Gout and Clonal Hematopoiesis

Abstracts: Innate Immunity

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].